ReviewArchivum immunologiae et therapiae experimentalis2023
Mast Cells and Resistance to Immunotherapy in Cancer.
Review in Archivum immunologiae et therapiae experimentalis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Continuous multi-omics pathway enrichment analysis resolves hidden functional heterogeneity.Briefings in bioinformatics · 2026Article
- Article
- <p>Tumor microenvironment in bone sarcomas: Implications for immunotherapy and emerging therapeutic vulnerabilities (Review)</p>.Oncology reports · 2026Review
- Tumor-Infiltrating Mast Cells Enhance Neoadjuvant Therapy Efficacy in ESCC via Modulation of the Desmoplastic Microenvironment.OncoTargets and therapy · 2026Article
- Tumor immune microenvironment in non-small cell lung cancer progression.Frontiers in immunology · 2026Review
- Epigenetic reprogramming of mast and cancer cells modifies tumor-promoting cytokine networks.Medical oncology (Northwood, London, England) · 2025Article
- The prognostic significance and Immunomodulatory role of SCGB3A1 expression in stage I lung adenocarcinoma.BMC medical genomics · 2025Article
- Single-cell transcriptomics and machine learning unveil ferroptosis features in tumor-associated macrophages: Prognostic model and therapeutic strategies for lung adenocarcinoma.Frontiers in pharmacology · 2025Article
- Interleukin-33 and Obesity-Related Inflammation and Cancer.Encyclopedia · 2024Article
- The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy.European journal of immunology · 2024Review
- Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer.Journal of ovarian research · 2024Article
- TimiGP-Response: the pan-cancer immune landscape associated with response to immunotherapy.bioRxiv : the preprint server for biology · 2024Article
- Prognostic role of macrophages and mast cells in the microenvironment of hepatocellular carcinoma after resection.BMC cancer · 2024Article
- Impaired Proliferation of CD8Journal of immunology research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cells are involved in tumor growth and their mediators exert both pro- and anti-tumorigenic roles in different human cancers. The identification of defined immunosuppressive pathways that are present in the tumor microenvironment has pointed therapeutic strategies that may promote inflammation and/or innate immune activation in this context. Mast cells can contribute to the immune suppressive tumor microenvironment and may also enhance anti-tumor responses. This review article is focused on the analysis of the mechanisms of the role of mast cells in resistance to immunotherapy in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.